Gastric Adenocarcinoma — Trials

Gastric Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

447 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 137
Recruiting: 69
Ph III recruiting: 12
Growth YoY: +31.3%
Industry share: 22%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 31.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (52)

clinicaltrialsPublishedShowing 51–83 of 83 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07266025	Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma：A Randomized, Non-comparative Phase 2 Study(CATALIS)	not yet recruiting	Phase 2	30	Shanghai Zhongshan HospitalOTHER	0	Jan 27, 2026	clinicaltrials
NCT03257163	Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer	active not recruiting	Phase 2	40	Rutgers, The State University of New Jersey